Deep Brain Stimulation (DBS)
Implanted electrodes that deliver electrical pulses to structures deep in the brain, an established therapy for Parkinson's disease and essential tremor with more than 200,000 recipients. Sensing-capable systems and add-on software therapies such as CereGate's are opening the installed base to new uses.
Overview
Deep brain stimulation (DBS) sends electrical pulses through leads implanted in deep brain structures, typically the subthalamic nucleus or globus pallidus in medication-refractory Parkinson’s disease. More than 200,000 people have received DBS devices. Conventional DBS stimulates without interpreting neural activity, which separates it from decoding brain-computer interfaces. The market is held by Medtronic (Activa and BrainSense adaptive DBS), Abbott (Infinity) and Boston Scientific (Vercise). Medtronic’s Percept, approved by the FDA in 2020, records local field potentials during stimulation through its BrainSense function. DBS pioneers Alim Louis Benabid and Pierre Pollak were among the 2026 Queen Elizabeth Prize for Engineering laureates.
Latest
CereGate, a Munich company, closed a Series C led by an unnamed US medtech company in October 2026. Its therapy for freezing of gait in Parkinson’s adds bursts of stimulation to conventional DBS, and in its US trial of up to 41 people it runs on Boston Scientific’s Gevia and Genus R16 pulse generators. The trial is due to finish main data collection in June 2027. Neuralink’s next-generation R1 robot, disclosed in May 2026, is designed to reach subcortical targets, opening Parkinson’s disease as a possible indication for the Neuralink N1. Implanted stimulation for depression has a weak record: Medtronic’s Reclaim DBS programme failed its pivotal trial in 2013, and Abbott’s BROADEN trial was halted for futility.
Why it matters
The installed base and established reimbursement make DBS hardware a platform for software therapies and new indications, the route CereGate is taking. Reimbursement is also under pressure. Since January 2026, DBS for essential tremor and Parkinson’s has required AI-assisted prior authorisation for traditional Medicare patients in six US states under the CMS WISeR pilot, which runs to 2031. For brain-computer interface developers, DBS is the benchmark for what a reimbursed brain implant looks like.
Coverage on InsideBCI
- 15 October 2026: CereGate raises Series C for a Parkinson’s walking therapy
- 5 July 2026: Nia Therapeutics gets FDA Breakthrough Designation for a preclinical TBI memory implant
- 22 May 2026: Neuralink’s surgical robot can now reach any region of the human brain, opening Parkinson’s, epilepsy and depression as new target indications
- 8 May 2026: Inspire takes the first quantified WISeR hit as Medicare bifurcates its neuromodulation posture
- 6 April 2026: GAO Names Neural Implants Among Three Emerging Priorities for Congress